Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)
Inclusion Criteria:
- women with histologically proven breast cancer (pT1/pT2/pT3, pN1, N0)
- ECOG performance status 0-1
- start of adjuvant therapy not later than 4 weeks after surgery
- hematology: platelets at least 100xGpt/l, neutrophiles at least 2xGpt/l
- normal liver function as defined by: bilirubine till 1.5 x normal value, SGOT/SGPT
till 1.25 x normal value
- normal kidney function as defined by: creatine till 1.5 x normal value
- negative pregnancy test for patients before menopause and effective contraception
- written informed consent
Exclusion Criteria:
- prior radiation, chemotherapy, hormontherapy and immunotherapy
- patients with more than 3 afflicted lymph nodes
- afflicted lymph nodes on the cantralateal side and/or afflicted supraclavicular or
intraclavicular lymph nodes
- bilateral breast cancer or second carcinoma of the breast
- inflammatory breast cancer and/or distant metastases
- existing clinically relevant peripheral neuropathie
- heart infection during the last 6 months or therapeutically not compensated heart
failure or cardiac arrhythmias of at least LOWN II
- patients with active infections and/or not controlled hypercalcemia
- pregnant or breastfeeding women or women of child-bearing age who do not use
effictive contrazeptiva